Identify the Right Endpoints in Rare Disease Trials

See how smarter endpoint strategies can reduce development risk and accelerate decision-making in oncology trials

Rare disease trials are particularly challenging because small patient populations and wide variation in symptoms make endpoint selection difficult. In this short video, Marc Buyse explains how IDDI designed and endpoint strategy to support US and European regulatory pathways in a Wilson's disease trial.

This case study illustrates how the right endpoint strategy can help you:

  • Maximize the value of clinical and biomarker data
  • Select meaningful endpoints across diverse patient populations
  • Support accelerated and full regulatory approval strategies
  • Improve decision-making in complex development programs

Explore Related Case Studies

Planning a rare disease or complex clinical trial?

Talk to our statistical experts about designing endpoints that support regulatory success while reflecting real patient outcomes.

By submitting this form, you agree to receiving commercial electronic messages such as emails from IDDI. For more info, please visit our Privacy Policy. You can unsubscribe at any time by clicking the 'unsubscribe' button at the foot of any email communication from IDDI.